Supported by the W.M. Keck Foundation and Seth MacFarlane Foundation

What is the USC COVID-19 Biospecimen Repository (Biorepository)?

The USC COVID-19 Biospecimen Repository (Biorepository) houses blood, saliva, urine, and/or tissue samples from patients who have confirmed positivity for COVID-19. This biorepository enables basic, translational, and clinical research in patients who have had COVID-19. The biorepository facilitates the study of the natural history, disease progression, and treatment response in patients with COVID-19. Samples from control patients are also collected. The specimens are banked for current and future research.

What Are We Collecting?  

  • Blood: plasma, serum, host DNA and RNA.
  • Viral RNA
  • Saliva
  • Urine
  • Optional: tissue, CSF, bronchioalveolar lavage, tears.

Link to Detailed Schedule of Sample Collection


  • Click here for additional information on purpose, study location, biorepository cohorts, types of biospecimen collected, and data collected.

If you are a USC principal investigator and have additional questions on how to obtain samples from the biorepository, please contact Ari Padilla, at Ariadna.Padilla@med.usc.edu

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

This program is open to all eligible individuals. SC CTSI operates all of its programs and activities consistent with the University’s Notice of Non-Discrimination. Eligibility is not determined based on race, sex, ethnicity, sexual orientation, or any other prohibited factor.